AstraZeneca (AZ; NASDAQ: AZN), headquartered in the UK, has announced a significant investment of $300 million to establish a next-generation cell therapies manufacturing facility in the United States. This new site is set to enhance support for global clinical trials and facilitate local product launches.
This strategic move follows AstraZeneca’s acquisition of Neogene Therapeutics, a specialist in engineered T cell receptor (TCR) therapies, in 2022, and its collaborations with cell therapy-focused companies such as Quell Therapeutics, AbelZeta, and Cellectis (OTCMKTS: CMVLF).
The upcoming facility will expand AstraZeneca’s global network, which currently includes nearly 30 manufacturing and supply sites that are either operational or in development.- Flcube.com
